Study the Safety and Efficacy of Probiotics Use in Premature Infants
Not Applicable
Withdrawn
- Conditions
- Infant, Premature, Diseases
- Registration Number
- NCT01891604
- Lead Sponsor
- University of Manitoba
- Brief Summary
Prophylactic enteral probiotics may enhance clinical markers and biomarkers of preterm infants' health, and may also play a role in reducing NEC and associated morbidity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- born with weight<1500 g
- hospitalized within 48 hours after birth
Exclusion Criteria
- present with evidence or suspicion of congenital intestinal obstruction
- perforation
- gastroschisis
- large omphalocele
- congenital diaphragmatic hernia
- major congenital heart defects
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Calprotectin will be used to determine the effect for probiotics day1 and day30 of the observation
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie probiotic efficacy in reducing NEC in preterm infants (NCT01891604)?
How do enteral probiotics compare to standard-of-care in preventing NEC and improving gut health in VLBW infants?
Which biomarkers correlate with improved clinical outcomes in preterm infants receiving prophylactic probiotics (NCT01891604)?
What adverse events are associated with probiotic administration in preterm neonates and how are they managed?
What combination therapies or alternative probiotic strains show promise for preterm infant gut health compared to NCT01891604 protocols?